Crossmark

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Crossref DOI link: https://doi.org/10.1016/S0140-6736(23)01055-3

Published Print: 2023-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Agarwal, Neeraj

Azad, Arun A

Carles, Joan

Fay, Andre P

Matsubara, Nobuaki

Heinrich, Daniel

Szczylik, Cezary

De Giorgi, Ugo

Young Joung, Jae

Fong, Peter C C

Voog, Eric

Jones, Robert J

Shore, Neal D

Dunshee, Curtis

Zschäbitz, Stefanie

Oldenburg, Jan

Lin, Xun

Healy, Cynthia G

Di Santo, Nicola

Zohren, Fabian

Fizazi, Karim
License Information

Text and Data Mining valid from 2023-07-01

stm-asf valid from 2023-07-01

stm-asf valid from 2023-07-01

stm-asf valid from 2023-07-01

stm-asf valid from 2023-07-01

stm-asf valid from 2023-07-01
More Information

This article is maintained by: Elsevier

Article Title: Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Journal Title: The Lancet

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(23)01055-3

CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(23)01123-6

Content Type: article

Copyright: © 2023 Elsevier Ltd. All rights reserved.

Updates are available Erratum dated 2023-07-22

Click to view Erratum: https://doi.org/10.1016/s0140-6736(23)01482-4